You are here
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Until May 19, 1972, the National Institute of Arthritis and Metabolic Diseases; until June 23, 1981, the National Institute of Arthritis, Metabolism, and Digestive Diseases; until April 8, 1986, the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) was established in 1986. The mission of the NIAMS is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.
The Institute also conducts and supports basic research on the normal structure and function of bones, joints, muscles, and skin. Basic research involves a wide variety of scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology, virology, and pharmacology. Clinical research includes rheumatology, orthopaedics, dermatology, metabolic bone diseases, heritable disorders of bone and cartilage, inherited and inflammatory muscle diseases, and sports and rehabilitation medicine.
November 20, 1985—The Health Research Extension Act of 1985 (P.L. 99-158) authorized the establishment of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
April 8, 1986—The NIAMS was established.
February 18, 1987—The first meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council was held.
April 15, 1996—The NIAMS held a 10th anniversary symposium: "Progress and Promise in Chronic Disease."
April 2006—The NIAMS celebrated its 20th anniversary.
June 13, 2011—The NIAMS hosted a scientific symposium: Improving Lives Through Discovery, one of many activities held throughout the year that recognized the 25th anniversary of the Institute. For more information, visit http://www.niams.nih.gov/25th_Anniversary/default.asp
August 1950—An arthritis program was established within the National Institute of Arthritis and Metabolic Diseases under Public Law 81-692.
May 1972—P.L. 92-305 renamed the Institute the National Institute of Arthritis, Metabolism, and Digestive Diseases.
1973—Senator Alan Cranston introduced legislation that would eventually lead to the National Arthritis Act. Companion legislation was introduced in the House by Congressman Paul Rogers.
January 1975—The National Arthritis Act (P.L. 93-640) established the National Commission on Arthritis and Related Musculoskeletal Diseases to study the problem of arthritis in depth and to develop an arthritis plan. The act also established the position of associate director for arthritis and related musculoskeletal diseases and authorized an interagency arthritis coordinating committee; community demonstration project grants; an arthritis data bank; an information clearinghouse; and comprehensive centers for research, diagnosis, treatment, rehabilitation, and education.
April 1976—After a year of study and public hearings, the commission issued a comprehensive plan aimed at diminishing the physical, economic, and psychosocial effects of arthritis and musculoskeletal diseases. It laid the groundwork for a national program encompassing research, research training, education, and patient care.
October 1976—The Arthritis, Diabetes, and Digestive Diseases Amendments of 1976 (P.L. 94-562) established the National Arthritis Advisory Board to review and evaluate the implementation of the Arthritis Plan, prepared in response to the National Arthritis Act (P.L. 93-640).
December 1980—P.L. 96-538 changed the name of the Institute to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. 1982—The U.S. Department of Health and Human Services (HHS) conferred bureau status on the Institute, resulting in creation of the Division of Arthritis, Musculoskeletal, and Skin Diseases and the appointment of a division director.
November 1985—The Health Research Extension Act of 1985, P.L. 99-158, established the National Institute of Arthritis and Musculoskeletal and Skin Diseases to bring increased emphasis to research on these disorders. The legislation provided for the development of a plan for a national arthritis and musculoskeletal diseases program, and establishment of two interagency coordinating committees, one on arthritis and musculoskeletal diseases and one on skin diseases. It also expanded the activities of the National Arthritis Advisory Board to include musculoskeletal and skin diseases.
September 1993—The NIH Revitalization Act of 1993 (P.L. 103-43) called on the NIAMS to establish "an information clearinghouse on osteoporosis and related bone disorders to facilitate and enhance knowledge and understanding on the part of health professionals, patients, and the public through the effective dissemination of information."
October 2000—The Children's Health Act of 2000 (P.L. 106-310) called on the NIAMS to expand and intensify research programs on juvenile arthritis and related conditions, in coordination with other NIH Institutes and the Arthritis and Musculoskeletal Diseases Interagency Coordinating Committee. Further language stipulated that the Institute's current information clearinghouse include resources on juvenile arthritis and associated conditions.
November 2000—The Lupus Research and Care Amendments of 2000, which passed as part of the Public Health Improvement Act (P.L. 106-505), required the NIAMS to expand and intensify research and related activities regarding lupus, and to coordinate such efforts with other NIH Institutes, as appropriate. Among other provisions, the bill called for information and education programs for health professionals and the public.
December 2001—The Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001, or the MD-CARE Act (P.L. 107-84), called on several components of the NIH, including the NIAMS, to enhance research on muscular dystrophy, including establishing Centers of Excellence.
February 2003—The Office of the Secretary, HHS, was called on to establish a Federal working group on lupus for the purpose of exchanging information and coordinating Federal efforts regarding lupus research and education initiatives (P.L. 108-7, Omnibus Appropriations Act for FY 2003). The NIAMS, as the lead Institute at the NIH for lupus research, was asked to lead this Federal working group. The group is comprised of representatives from all relevant HHS agencies and other Federal departments having an interest in lupus.
October 2008—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education (MD-CARE) Amendments of 2008 (P.L. 110-361) officially named the muscular dystrophy Centers of Excellence as the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. In addition, the Muscular Dystrophy Coordinating Committee was authorized to give special consideration to enhance the clinical research infrastructure to test emerging therapies for the various forms of muscular dystrophy.
September 2014—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2014 (P.L. 113-166) made several changes to the program’s authorization, including expanding the types of muscular dystrophy for which NIH must conduct research, expanding the membership of the MDCC and requiring it to meet two times each year, and expanding the items to be covered in the Action Plan for the Muscular Dystrophies.
Stephen I. Katz, M.D., Ph.D., has been Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases since August 1995, and is also an Adjunct Investigator in the Dermatology Branch of the National Cancer Institute. He was born in New York in 1941 and his early years were spent in the Washington, D.C., and Bethesda, Maryland areas. After attending the University of Maryland, where he graduated with honors, he graduated from the Tulane University Medical School with honors in 1966. He completed a medical internship at Los Angeles County Hospital and did his dermatology residency at the University of Miami Medical Center from 1967 to 1970. He served in the U.S. military at Walter Reed Army Medical Center from 1970 to 1972. From 1972 to 1974, Dr. Katz did a postdoctoral fellowship at the Royal College of Surgeons of England and obtained a Ph.D. degree in immunology from the University of London in 1974. He then became Senior Investigator in the Dermatology Branch of the National Cancer Institute and assumed the position of Acting Chief in 1977. In 1980, he became Chief of the Branch, a position he held until 2002. In 1989, Dr. Katz also assumed the position of Marion B. Sulzberger Professor of Dermatology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, a position he held until 1995.
Dr. Katz has focused his studies on immunology and the skin. His research has demonstrated that skin is an important component of the immune system both in its normal function and as a target in immunologically-mediated disease. In addition to studying Langerhans cells and epidermally-derived cytokines, Dr. Katz and his colleagues have added considerable new knowledge about inherited and acquired blistering skin diseases.
Dr. Katz has trained a large number of outstanding immunodermatologists in the U.S., Japan, Korea, and Europe. Many of these individuals are now leading their own high-quality independent research programs. He has served many professional societies in leadership positions including the Society for Investigative Dermatology and the Association of Professors of Dermatology, as Secretary-General of the 18th World Congress of Dermatology in New York in 1992, as Secretary-Treasurer of the Clinical Immunology Society, and as President of both the International League of Dermatological Societies and the International Committee of Dermatology. He has also served on the editorial boards of a number of clinical and investigative dermatology and immunology journals. His honors and awards include the Master Dermatologist Award and the Sulzberger Lecture Award of the American Academy of Dermatology; the National Cancer Institute’s (NCI’s) Outstanding Mentor Award; the Harvey J. Bullock, Jr., EEO Award in recognition of his extraordinary leadership in scientific, programmatic, and administrative arenas; the Excellence in Leadership Award from the International Pemphigus Foundation; the "Change It" Champion Award from Parent Project Muscular Dystrophy; the Paul G. Rogers Leadership Award from the National Osteoporosis Foundation; the American Society for Bone and Mineral Research Distinguished Leader Award; the Dermatology Foundation Lifetime Career Educator Award; the American Skin Association Leadership in Academic Medicine Award; honorary memberships in the American Academy of Dermatology and the Society for Investigative Dermatology, as well as in numerous international dermatological societies; and election into the National Academy of Medicine of the National Academy of Sciences (USA). He has also received the Alfred Marchionini Gold Medal; the Gold Medal from the International League of Dermatological Societies for Achievements in Global Dermatology; the Lifetime Achievement Award of the American Skin Association, the Rothman Award for distinguished service to investigative cutaneous medicine, and the Kligman/Frost Award, the latter two from the Society for Investigative Dermatology. He received Doctor Honoris Causa degrees from Semmelweis University in Budapest, Hungary; Ludwig Maximilian University in Munich, Germany; the University of Athens in Greece; and the University College Dublin in Ireland. Dr. Katz has been honored by the Japanese government from which he received the Order of the Rising Sun, Gold Rays with Neck Ribbon from the Japanese Emperor. He was the recipient of the 7th Alan Rabson Award for NCI Intramural Cancer Research, has twice received the Meritorious Rank Award and has also received the Distinguished Executive Presidential Rank Award, the highest honor that can be bestowed upon a civil servant.
|Name||In Office from||To|
|Lawrence E. Shulman, M.D., Ph.D.||April 1986||October 1994|
|Michael D. Lockshin, M.D. (Acting)||November 1994||July 1995|
|Stephen I. Katz, M.D., Ph.D.||August 1995||Present|
The NIAMS supports a multidisciplinary program of basic, clinical, and translational investigations; epidemiologic research; research centers; and research training for scientists within its own facilities as well as grantees at universities and medical schools nationwide. It also supports the dissemination of research results and information through the National Institute of Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse and through the NIH Osteoporosis and Related Bone Diseases~National Resource Center.
The NIAMS Extramural Program supports research via grants and contracts in two Divisions: the Division of Skin and Rheumatic Diseases and the Division of Musculoskeletal Diseases. A wide array of basic, translational, and clinical research and research training in the fields of rheumatology, muscle biology, orthopaedics, bone and mineral metabolism, and dermatology is being pursued through these programs.
The Intramural Research Program of the NIAMS conducts innovative basic, translational, and clinical research relevant to the health concerns of the Institute and provides training for investigators interested in careers in these areas. The ultimate goals are: 1) to provide new insights into the normal function of bones, joints, muscles, and skin, and diseases that affect them; and 2) to generate a cadre of well-trained investigators to continue toward a complete understanding of these structures and the disease conditions that affect them adversely.
Extramural Research Program
Most funding from the NIAMS supports investigators involved in a wide spectrum of basic, clinical, epidemiologic, training, and other programs in universities, medical schools, academic health centers, and small business concerns; i.e., the extramural research community. The NIAMS Extramural Program's three Divisions—the Division of Extramural Research Activities, the Division of Skin and Rheumatic Diseases, and the Division of Musculoskeletal Diseases—are as follows:
Division of Extramural Research Activities
This Division manages the NIAMS grants policies and procedures, including oversight of grants and contracts administration, scientific review, and clinical research functions. It serves as the primary liaison for the NIAMS with the NIH Office of Extramural Research and with other Institutes that share research interests. The Division handles scientific integrity and ethical questions in research and manages the NIAMS Advisory Council, a congressionally mandated second tier of the NIH peer review system.
The Scientific Review Branch (SRB) conducts initial peer review of specific research applications assigned to the NIAMS. These include applications for Centers, program projects, multi-site clinical trials, scientific meetings, and training and career development awards, as well as applications responding to initiatives published by the NIAMS. External peer reviewers selected from the grant community conduct reviews.
The Grants Management Branch (GMB) works with scientists and institutional research administrators to issue, manage, and close out awards. The branch has legal responsibility for the fiscal management of the Institute's extramural grants and contracts.
Division of Skin and Rheumatic Diseases
The mission of this Division is to promote and support basic, translational, and clinical studies of skin, wound healing, skin disorders, as well as adult and pediatric rheumatic diseases. Approaches supported may include, but are not limited to, molecular and cell biology research; animal model construction; genetics and genomics research; identification of risk factors; autoimmunity and inflammation research; biopsychosocial/behavioral research; outcomes and health services research; clinical trials and research leading to prevention, diagnosis, control, and cure of these disorders. Research is managed under two main areas:
Arthritis and Rheumatic Diseases. The overall goals of the programs in this area are to advance high-quality basic, translational, and clinical research in a number of autoimmune and arthritis-related chronic disorders. These include, but are not limited to, the adult diseases of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE or lupus), scleroderma, vasculitis, the spondyloarthropathies (e.g., ankylosing spondylitis, psoriatic arthritis), gout, fibromyalgia, and Sjögren’s syndrome. Others include pediatric diseases, such as juvenile idiopathic arthritis, periodic fever syndromes, and juvenile lupus. The programs also support studies focused on the natural history of these disorders, as well as basic biology of autoimmunity and inflammation, to better understand the molecular mechanisms underlying these processes, with the goal of finding ways to interrupt them and improve patient outcomes. The NIAMS is committed to pursuing new opportunities in genetics and genomics research, clinical trial design, pain, and biopsychosocial aspects of diseases in this portfolio. It is also committed to identification of risk factors for these disorders, enhancement of disease prediction, and advancement of prevention strategies.
Skin Biology and Diseases. The programs in these areas support a broad portfolio of basic, translational, and clinical research in skin. These efforts include work on the developmental and molecular biology of skin and skin appendages (such as the hair follicle), the study of skin as an immune organ, and the genetics of skin diseases. Areas of particular emphasis include: investigations of stem cells found in skin; studies related to wound healing and fibrosis; heritable disorders of connective tissue (such as Marfan’s syndrome); studies related to itch; metabolic studies of skin, such as the effects of hormones and the role of enzymes in skin barrier formation; and immunologically mediated cutaneous disorders, such as atopic dermatitis, contact dermatitis, and vasculitis. Research is underway to better understand keratinizing and inflammatory disorders such as psoriasis and ichthyosis; disorders of pigmentation such as vitiligo; and bullous diseases such as pemphigus, pemphigoid, and epidermolysis bullosa. Other studies encompass acne and the physiologic activity of the sebaceous glands, as well as disorders of the hair, such as alopecia areata. Tremendous opportunities exist in the area of skin diseases research, both within the field and at the interface with other mature and emerging areas (e.g., systems biology, circadium rhythms, neurobiology, extracellular RNA communication), which provide fertile ground for work directed toward a deeper understanding of the basic biology of skin functions, to new approaches for developing artificial skin, to advances in imaging technologies for diagnosis and tracking of skin disease progression. The NIAMS is committed to pursuing these and other avenues of research to improve health outcomes for patients with skin diseases.
Division of Musculoskeletal Diseases
This Division supports research aimed at improving the diagnosis, treatment, and prevention of both common and rare diseases and of injuries to the musculoskeletal system and its component tissues. The musculoskeletal system is comprised of the skeleton, which provides mechanical support and determines shape; the muscles, which power movement; and connective tissues such as tendons and ligaments, which hold the other components together. The cartilage surfaces of joints and the intervertebral discs of the spine, which allow for movement and flexibility, are also included.
Key public health problems addressed by this research include osteoporosis, osteoarthritis, back pain, and muscle disorders, including muscular dystrophy. Research is conducted at every level, from fundamental biology to prevention and clinical intervention of musculoskeletal conditions and diseases. Basic, translational, and clinical research are managed under three main areas:
Bone Biology and Diseases. The programs in these areas cover a broad spectrum of research to better understand the genetic, molecular and cellular mechanisms involved in bone biology; the development of common and rare bone diseases; and the structural integrity of bone. Research areas include the mechanisms of bone formation, resorption, and mineralization; the effects of hormones, growth factors, and other signaling molecules on these processes; regulation of the growth plate; and the interaction of bone with other tissues and organs. The programs also emphasize the application of fundamental knowledge of bone biology to the development of drug and gene therapies for bone diseases. This NIAMS component supports several epidemiologic cohorts for the characterization of the natural history of osteoporosis and rare bone diseases and disorders. Like other cohort studies supported by the NIAMS, their ultimate goal is to contribute to the development of better prevention strategies, diagnostic tools, and treatments.
Muscle Biology and Diseases. The programs in these areas support a wide range of basic, translational, and clinical research projects in skeletal muscle biology and diseases. They focus on the fundamental biology of muscle development, physiology, and muscle imaging. Particular interests include the basic biology of satellite and muscle stem cells, excitation-contraction coupling, muscle metabolism, and adaptation of muscle to exercise. The programs address a need for translational research to develop discoveries that enhance treatment and improve management of muscle and musculoskeletal diseases and disorders with a focus on the interaction of muscle with other organs and tissues. The overarching objective is to advance the understanding of—and ultimately prevent and treat—muscular dystrophies, inflammatory myopathies, muscle ion channel diseases, and muscle disorders such as disuse atrophy and age-related loss of muscle mass.
Musculoskeletal Biology and Diseases. The programs in these areas focus on understanding the fundamental biology of joints and their component tissues, and on translating and applying this knowledge to a variety of diseases and conditions. Research includes the study of the causes and treatment of acute and chronic injuries—including fractures, tendon and ligament injury and repair, and low back pain—as well as clinical and epidemiological studies of osteoarthritis. The programs support the development of new technologies such as methods for imaging bone and cartilage to improve the diagnosis and treatment of skeletal disorders, or to facilitate the repair of damage caused by trauma to otherwise healthy musculoskeletal tissues including bone, cartilage, tendon, ligament, intervertebral disc, and meniscus. Therapeutic approaches of interest in the programs include drugs, nutritional interventions, joint replacement (including biomaterials and implant science), bone and cartilage transplantation, and gene therapy. Tissue engineering, regenerative medicine, sports medicine, and musculoskeletal fitness are some areas of special emphasis.
Intramural Research Program
The NIAMS Intramural Research Program (IRP) consists of: Office of the Scientific Director, Office of the Clinical Director, Autoimmunity Branch, Clinical Trials and Outcomes Branch, Community Research and Care Branch, Laboratory of Molecular Immunogenetics, Laboratory of Muscle Stem Cells and Gene Regulation, Laboratory of Oral Connective Tissue Biology, Laboratory of Skin Biology, Laboratory of Structural Biology Research, Molecular Immunology and Inflammation Branch, Office of Science and Technology, Pediatric Translational Research Branch, Protein Expression Laboratory, Systemic Autoimmunity Branch, Rheumatology Fellowship and Training Branch, and the Career Development and Outreach Branch.
Office of the Scientific Director
The Office of the Scientific Directoris responsible for the development of broad decisions concerning program planning, budget and policy formulation, and resource allocation of the intramural program. The Scientific Director represents the NIAMS in discussions of NIH-wide intramural policies and programs, and serves as a vital member of the senior staff of the Institute. The Scientific Director serves as the principal advisor to the Director of the NIAMS concerning all ongoing and projected intramural research programs.
Office of the Clinical Director
The Office of the Clinical Director implements innovative clinical research programs that relate to the broad fields of rheumatologic, musculoskeletal, and skin disorders. Through specific programs in clinical research, rheumatology fellowships and advanced training in translational medicine, and health partnerships, the Office of the Clinical Director plays an important role in establishing cutting-edge therapeutic paradigms, in providing medical education in the field of rheumatology, and in reaching out to the community to reduce health care disparities and to improve the understanding of rheumatic and related diseases. The Translational Genetics and Genomics Unit in the Office of the Clinical Director focuses on understanding the mechanisms that underlie human inflammatory disease. Using an approach that integrates genomics, bioinformatics, and mechanistic investigations, the program aims to identify the causes of genetically complex autoinflammatory diseases, including systemic juvenile idiopathic arthritis and Behçet’s disease.
The Clinical Trials and Outcomes Branch conducts research on the health outcomes of patients with rheumatic diseases and orthopaedic conditions. Studies focus on the development and testing of measures of health and disease, identification of predictors of good and poor health outcomes, examination of treatment effectiveness, and investigations of socioeconomic and ethnic disparities in health outcomes. The Clinical and Investigative Orthopaedics Surgery Unit of the Clinical Trials and Outcomes Branch conducts studies on the outcomes of many important orthopaedic conditions. The studies use large clinical databases to investigate rare femur fractures, uncommon hip infections, and novel fracture treatments. The goal is to provide clinical insights into conditions that cannot be examined in traditional clinical studies.
The Community Research and Care Branch coordinates activities at the NIAMS Community Health Clinic, a health information resource and medical center that carries out research and provides health care services to people affected by arthritis, lupus, and other rheumatic diseases. The Clinic offers patient care with access to specialists, education programs, and referral to clinical investigations for the prevention and treatment of rheumatic diseases.
The Autoimmunity Branch conducts basic and clinical research on the pathophysiology and treatment of autoimmune diseases. Signal transduction pathways that differentiate normal and pathological immune responses are studied in mouse models and human tissue samples to gain insights into how these processes drive autoimmune diseases, and how therapies that minimize generalized immune suppression can best be developed for these diseases.
The Immunoregulation Section of the Autoimmunity Branchfocuses onthe TNF-family of cytokines and their receptors, from basic investigation of the trafficking and signaling by these molecules to the study of human diseases involving TNF-family cytokines and their receptors.
The Immunodeficiency and Inflammation Unitof the Autoimmunity Branch aims to understand fundamental signaling processes that lead to immune-mediated disease by focusing on the molecular mechanisms involved in the activation and regulation of the NF-kB family transcription factors. The unit established a genetics research program to evaluate individuals with known or currently undiagnosed rare genetic syndromes characterized by phenotypes of autoimmunity or inflammatory disease in the setting of immune deficiency.
The Laboratory of Molecular Immunogenetics conducts research on genetic and molecular regulation of normal and abnormal immune cell processes. The Lab, which includes the Genomics and Immunity Section, seeks to understand the molecular underpinnings of how inflammation is regulated in both health and disease. This knowledge can be applied to the development of targeted therapeutic agents that can ameliorate immune system disorders with minimal side effects.
The Laboratory of Muscle Stem Cells and Gene Regulation investigates the cellular and molecular mechanisms that regulate differentiation and regeneration of skeletal muscle in physiological and pathological conditions. The ultimate goal of these studies is to provide a conceptual, as well as practical, framework for the diagnosis and treatment of human diseases affecting skeletal muscle. The Lab includes the RNA Molecular Biology Group, which focuses on dissecting the composition of ribonucleoproteins involved in cellular RNA transport and control of RNA stability, and the Muscle Disease Unit, which focuses on human muscle disease as well as the basic biology of skeletal muscle regeneration.
The Laboratory of Oral Connective Tissue Biology studies the molecular biology of dental-oral-craniofacial development, with a focus on the teeth, gums, and related jaw structure. The aim of these studies is to understand cells and signals influencing tooth, bone, and periodontal ligament development in order to identify improved regenerative strategies.
The Laboratory of Skin Biology, which includes the Developmental Skin Biology Section, conducts research on the regulation of epidermal differentiation, skin barrier formation, and inflammatory responses associated with barrier dysfunction. A major focus is basic investigation of ectodermal appendage development and the study of human ectodermal dysplasias.
The Laboratory of Structural Biology Research conducts research into the structural basis of the assembly and functioning of macromolecules and their complexes (such as viruses and cytoskeletal proteins), and the mechanisms and proteins that control their assembly. These studies make extensive use of cryoelectron microscopy and three-dimensional image processing in studies of virus infection and replication; renewal of the epidermis, with maintenance of barrier function; prionogenesis (structural transitions of infectious proteins called prions); and intracellular protein quality control by energy-dependent proteases.
The Molecular Immunology and Inflammation Branch conducts basic and clinical investigations of the molecular mechanisms underlying immune and inflammatory responses in rheumatic and autoimmune diseases. A major focus is the study of receptor-mediated signal transduction and how these processes link to the regulation of genes involved in inflammatory responses.
The Autoinflammatory Pathogenesis Unit aims to clarify the pathogenic factors leading to hemophagocytic disorders by carefully evaluating affected patients, human cell lines, and murine models. The Unit has a particular focus on Macrophage Activation Syndrome (MAS). By studying how activation of different inflammasomes can have different effects at the cellular and organism levels, the Unit hopes to shed light on the basic biology underpinning MAS, disorders at risk for MAS, and phenotypically distinct inflammasomopathies.
The Office of Science and Technology encompasses an infrastructure of research and support facilities designed to enhance the research capabilities of all IRP scientists. In addition, staff members advise the Scientific Director, Laboratory and Branch Chiefs, and other key officials on collaborative and cooperative activities, training programs, and proper use of laboratory animals. Staff members also negotiate and facilitate scientific collaborations that involve trans-Institute and trans-NIH initiatives and agreements. The Office includes the following:
- The Flow Cytometry Section provides state-of-the-art multiparameter analytic and cell sorting capabilities for IRP investigators.
- The Laboratory Animal Care and Use Section supports all IRP Branches and Laboratories that utilize animal models in their research initiatives.
- The Light Imaging Section offers IRP scientists access to state-of-the-art light imaging equipment and expertise in light microscopy techniques.
- The Biodata Mining and Discovery Section assists with computational and bioinformatics approaches to support NIAMS intramural research.
- The Translational Immunology Section provides NIAMS investigators with services, consultative advice, and in-depth instructions in a variety of immunologic methods to interpret immunoassays.
The Pediatric Translational Research Branch, which includes the Translational Autoinflammatory Disease Section, conducts basic, translational, and clinical research to dissect the pathways involved in the pathogenesis of immune-mediated inflammatory diseases. The mechanisms by which specific gene mutations and polymorphisms predispose to inflammation, and how they contribute to unique phenotypic manifestations of individual diseases, are being investigated using a variety of approaches.
The Protein Expression Laboratory plans and conducts research on the expression, purification, and structural characterization of human immunodeficiency virus (HIV) and HIV-related proteins. Laboratory scientists also collaborate with NIH intramural researchers studying the structure and function of HIV and HIV-related proteins. The Lab serves as a support and resource group for the expression and purification of these proteins.
The Systemic Autoimmunity Branch focuses on unraveling the fundamental mechanisms that lead to the development and perpetuation of systemic autoimmune disorders, particularly systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and their associated organ damage. By identifying the mechanisms of tissue damage in SLE and RA, the Branch is exploring whether specific pharmacologic interventions that block identified pathways can mitigate complications in these and other immune disorders. The Vasculitis Translational Research Program based in the Systemic Autoimmunity Branch develops clinical and translational research initiatives across many types of systemic vasculitis. The program’s key objectives include comprehensive clinical evaluation of patients with known or suspected vasculitis, assessment of vascular inflammation through imaging studies, discovery of novel biomarkers through genomic profiling, and clinical trials of novel therapeutics. The program works closely with the NIH Clinical Center, and has established an ongoing collaboration with the international NIH-funded Vasculitis Clinical Research Consortium.
The Rheumatology Fellowship and Training Branch is dedicated to the clinical and research training of physicians wishing to pursue careers in biomedical or translational research related to rheumatic diseases. Led by the NIAMS, the NIH Rheumatology Training Program is two years in duration, with extensions available for individuals interested in advanced research training as NIAMS Scholars in Translational Medicine. The program is accredited by the Accreditation Council for Graduate Medical Education (ACGME), and graduates are eligible to sit for the certifying examination in the subspecialty of rheumatology.
The Career Development and Outreach Branch advises the Scientific Director, Laboratory and Branch Chiefs, and other key officials within the NIAMS IRP on current and potential training programs; coordinates resources available for NIAMS fellows and their sponsors; and works in partnership with existing NIAMS and NIH components to ensure that the NIAMS continues to attract the highest caliber of trainees at the postdoctoral, postbaccalaureate, and graduate student levels. The Branch enables NIAMS fellows to become leaders in the biomedical research community and provides trainees with a genuine growth experience, enhancing their ability to compete for independent research or other science-related careers in government or the private sector. In addition, the Branch leads Institute career outreach activities, administers the summer internship program, and supports the annual NIAMS Intramural Scientific Training.
This page last reviewed on February 28, 2017